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InteractionAbstract Present study investigated the potential effects of Ferula asafetida resin on metabolic
activities of human drug metabolizing enzymes: CYP2D6 and CYP3A4. Dextromethorphan
(DEX) was used as a marker to assess metabolic activities of these enzymes, based on its CYP2D6
and CYP3A4 mediated metabolism to dextrorphan (DOR) and 3-methoxymorphinan (3-MM),
respectively. In vitro study was conducted by incubating DEX with human liver microsomes and
NADPH in the presence or absence of Asafetida alcoholic extract. For clinical study, healthy
human volunteers received a single dose of DEX alone (phase-I) and repeated the same dose after
a washout period and four-day Asafetida treatment (phase-II). Asafetida showed a concentration
dependent inhibition on DOR formation (in vitro) and a 33% increase in DEX/DOR urinary
metabolic ratio in clinical study. For CYP3A4, formation of 3-MM in microsomes was increased
at low Asafetida concentrations (10, 25 and 50 lg/ml) but slightly inhibited at the concentration
of 100 lg/ml. On the other hand, in vivo observations revealed that Asafetida signiﬁcantly increased
DEX/3-MM urinary metabolic ratio. The ﬁndings of this study suggest that Asafetida may have a
signiﬁcant effect on CYP3A4 metabolic activity. Therefore, using Ferula asafetida with CYP3A4
Modulation of metabolic activities of CYP2D6 and CYP3A4 by asafetida 565drug substrates should be cautioned especially those with narrow therapeutic index such as
cyclosporine, tacrolimus and carbamazepine.
ª 2014 King Saud University. Production and hosting by Elsevier B.V. This is an open access article under
the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
Numerous studies have reported that traditional medicines
may modulate the metabolic activity of cytochrome P-450
enzymes (CYP). Since, the use of traditional medicines is wide-
spread in developing countries, so the extent of modulation of
metabolizing enzymes needs to be assessed (Bhattaram et al.,
2002; Mukherjee and Wahile, 2006; Mu¨ller and Kanfer,
2011). CYP modulating herbs may also inﬂuence the metabo-
lism of co-administered CYP drug substrates. Such incidences
may lead to altered bioavailability and pharmacokinetics of
co-administered substrates (Mu¨ller and Kanfer, 2011; Izzo
and Ernst, 2001). Further, the consequences will be more seri-
ous with narrow therapeutic index drugs (Barone et al., 2001).
Several incidences of herb-drug interactions based on modula-
tion of CYP enzymes are reported (Fang et al., 2011; Ho et al.,
2011; Han et al., 2011; Boullata, 2005; Doehmer and
Eisenbraun, 2012). In humans most of the drugs are metabo-
lized by CYP3A4, CYP2D6, CYP2C19, CYP2C9, CYP2E1
and CYP1A2 (Zhou, 2008; Lee et al., 2013a,b). Geum chilo-
ense (‘‘hierba del clavo’’) increases the blood concentration
of cyclosporine, while ginger has the opposite effect (Duclos
and Goecke, 2001; Chiang et al., 2006). Myricetin inhibited
the drug metabolizing enzymes CYP3A4 and CYP2C9 (Choi
et al., 2010). St John’s wort induces CYP3A4 isoenzyme and
P-glycoprotein; and has been reported to reduce the blood
level of digoxin, cyclosporine, tacrolimus, amitriptyline,
midazolam, warfarin, indinavir, phenprocoumon and theoph-
ylline (Barone et al., 2001; Hu et al., 2005; Izzo, 2005). Septilin
signiﬁcantly decreased the T1/2a, T1/2e, AUC0-inf, Cmax and
AUC0–24 of carbamazepine (Garg et al., 1998). Sho-seiryu-to
extract powder delays the absorption and accelerates carbam-
azepine metabolism (Ohnishi et al., 1999). Ginkgo ﬂavonoids
increased the activity of CYP3A4 (Diamond et al., 2000).
Ferula asafetida L. belongs to family apiaceae. Its oleo-gum
resin is obtained by incising or cutting the living roots and rhi-
zomes. The resin is solid or semisolid with alliaceous odor and
a bitter acrid taste. The resinous material comprises ferulic acid,
umbelliferone, asaresinotannols, umbelliferone ethers, gums
and volatile oils. The sulﬁdes of volatile oils are responsible
for the characteristic ﬂavor of Asafetida (Sadraei et al., 2003;
Kajimoto et al., 1989). Asafetida has been used as a folk medi-
cation for various ailments including ﬂatulence, cough, asthma,
bronchitis, hysteria, and convulsions (Eigner and Scholz, 1999).
Present study assesses the potential effects of F. asafetida on
the metabolic activities of hepatic metabolizing enzymes
CYP3A4 and CYP2D6 using dextromethorphan (DEX) as a
probe. In vitro investigations were carried out by using human
liver microsomes, while an in vivo study was conducted in
healthy human subjects. In liver, DEX is mainly metabolized
through N- and O-demethylations. The O-demethylation of
DEX to dextrorphan (DOR) is predominantly mediated by
CYP2D6 (Barnhart, 1980; Schadel et al., 1995). Therefore,
DEX is commonly used as a marker for CYP2D6 activity
(Kerry et al., 1994; Hu et al., 1998; Takashima et al., 2005;Wojtczak et al., 2007). The N-demethylation of DEX to 3-
methoxymorphinan (3-MM) is mediated by CYP3A4
(Gorski et al., 1994). So, DEX has been used as a common
probe for both CYP3A and CYP2D6 activities (Spanakis
et al., 2009; Yu and Haining, 2001), as well as in vivo in several
studies (Ducharme et al., 1996; Funck-Brentano et al., 2005;
Jones et al., 1996).2. Materials and methods
Nicotinamide adenine dinucleotide phosphate (NADPH) and
b-glucuronidase (76,800 U/ml) were purchased from Helix
Pomatia, ICN Biomedicals Inc., Costa Mesa, AC, USA. The
syrup of dextromethorphan hydrobromide was obtained from
Riyadh Pharma, Medical and Cosmetic products Co. Ltd.,
Riyadh, Saudi Arabia. Dextromethorphan (DEX) hydrobro-
mide, dextrorphan hydrobromide and 3-methoxymorphinan
hydrobromide were purchased from ICN Biomedicals Inc.,
Warrenale, USA. Human liver microsomes having a protein
concentration of 20 mg/ml were purchased from Human Biol-
ogics International LLC (HBI, Scottsdale, USA), shipped in
small vials with dry ice and stored in a deep freezer at
80 C. F. asafetida dried resin was purchased from the local
Saudi Market. The internal standards codeine and betaxolol
were of USP reference standard. General-purpose reagents
(GPR) were used for extraction processes, while HPLC grade
solvents were used for HPLC determinations. All other mate-
rials were of analytical grade.
2.1. Extract of plant material
Dried Asafetida resin was purchased from the Saudi market
and grounded to a ﬁne powder. This dried resin powder was
exhaustively extracted with ethanol for ﬁve days by the cold
maceration process. The ethanolic extract of the resin was ﬁl-
tered and concentrated under reduced pressure using a rota-
tory evaporator. The extract was weighed and its serial
dilutions were made with ethyl alcohol (96%) to prepare stock
solutions of 1.25, 2.5, 5, 25 and 50 mg/ml concentrations.
These stock solutions were stored in a refrigerator until used
for incubation.
2.2. Microsomal incubation
Methanolic solution of dextromethorphan (25 lM concentra-
tion per ﬁnal incubation mixture) was transferred into eppen-
dorf tubes and dried with the help of nitrogen. The human
liver microsomes (comprising 0.25 mg protein/ml) and appro-
priate volume of potassium phosphate buffer (0.1 M, pH 7.4)
were added to the DEX loaded tubes and gently mixed. This
mixture of DEX, microsomes and buffer was pre-incubated
at 37 C for 3 min in a shaker water bath. The metabolic reac-
tion was initiated by adding 1 mM NADPH in a ﬁnal volume
of 0.5 ml. Reaction was allowed for 30 min in the absence
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Figure 1 Effect of Asafetida on the formation of DOR from
DEX in human liver microsomes (n= 3, mean ± SD). Formation
of the metabolite is expressed as nM/mg protein/min. *P 6 0.05.
566 F.I. Al-Jenoobi et al.(control) or in the presence of 10 ll Asafetida resin extract (at
concentrations of 10, 25, 50 or 100 lg/ml). The metabolic reac-
tion was terminated by adding 10 ll of perchloric acid (70%)
with 2–3 min of vigorous shaking. The 25 ll of internal stan-
dard (codeine 50 lg/ml) was added to each tube and the tubes
were centrifuged at 10,000 rpm for 15 min. The supernatant
was separated and transferred into a clean vial and analyzed
by HPLC.
2.3. Clinical study
A clinical study was conducted in nonsmoking, healthy volun-
teers (2 males and 4 females) of ages 18–35 years. Study proto-
col was explained to each volunteer and written informed
consent was received from them. Study protocol was approved
by the Ethics Committee at the College of Medicine, King
Saud University; Riyadh (approval number is 1426037). The
subjects were instructed not to take caffeine or products com-
prising caffeine, for at least 24 h before dosing. Further, none
of these subjects was receiving any other traditional or conven-
tional medications or grapefruit comprising products for at
least 2 weeks before and during the study. The clinical study
was carried out in two phases with a washout period of two
weeks. In phase-I, all subjects received a single dose of dextro-
methorphan (10 ml of DEX hydrobromide syrup (15 mg/5 ml).
In phase-II, powder of Asafetida resin was administered orally
in a dose of 1.0 g twice a day for four consecutive days. On the
last day of dosing, subjects received 30 mg DEX (10 ml of
15 mg/5 ml syrup) and Asafetida resin, simultaneously. The
subjects abstained from food for two hours before and after
DEX dosing and were instructed to empty their bladder pre-
dosing. Urine samples were collected and kept at 20 C until
analyzed by HPLC. The urinary metabolic ratios of DEX/3-
MM and DEX/DOR were used as indices to metabolic activ-
ities of CYP3A4 and CYP2D6 enzymes, respectively.
2.4. Preparation of urine samples
The collected urine samples were hydrolyzed by b-glucuroni-
dase (19,200 U/ml, incubated for 18 h) to obtain unconjugated
DEX and its metabolites. 1 ml of hydrolyzed urine was vigor-
ously mixed with 5 ml of extracting solvent mixture (diethyl
ether: chloroform: propranolol, 20:9:1 v/v/v) in a clean tube.
The tube was centrifuged at 14,500g for 10 min. The organic
layer was separated and vigorously mixed with 300 ll of
0.1 N hydrochloric acid and centrifuged at 14,500g for
10 min. The aqueous layer was separated and betaxolol
(50 ll of 50 lg/ml) was added as internal standard to each
sample. Samples were analyzed by using HPLC.
2.5. Determination of DEX metabolites in human liver
microsomes and urine
DEX and its metabolites were analyzed by Shimadzu Class-
VPV 5.02 HPLC instrument using two slightly different
analytical methods (Bendriss et al., 2001; Min et al., 1999).
The human liver microsomal analytes were eluted on a
Nova-Pak phenyl column (5 lm, 150 · 3.9 mm) using a
mobile phase that was composed of an aqueous mixture
(1.5% glacial acetic acid and 0.1% triethylamine) and
acetonitrile (75:25 v/v), and ﬂowing at a rate of 1 ml/min. Urinesamples were eluted on a Zorbax SB-CN column (5 lm,
250 · 4.6 mm). The mobile phase for analysis of urine samples
was composed of the aqueous mixture (1.5% glacial acetic acid
and 0.1% triethylamine) and acetonitrile (87.5:12.5 v/v). The
pH of the mobile phase was adjusted to 3 by orthophosphoric
acid. Analytes were monitored using a ﬂuorescence detector at
excitation and emission wavelengths of 280 and 330 nm, respec-
tively. Concentrations of DEX and its metabolites in samples
were estimated based on the calibration curves of the analytes.
2.6. Statistical analysis
The in vitro formation of DEX metabolites in the presence of
Asafetida was compared with the control by using a one-way
analysis of variance (ANOVA), and a Post hoc Scheffe’s multi-
ple comparison test with a signiﬁcant P value 60.05. Student’s
paired t-test was used for statistical analysis of results obtained
from clinical study. Statistical analysis was performed by using
Graph-Pad Prism version 3.0 for Windows (San Diego, CA,
USA).
3. Results
In the in vitro study, Asafetida resin alcoholic extract inhib-
ited the formation of DOR from DEX in a concentration
dependent manner (Fig. 1). Formation of 3-MM was poten-
tiated at lower concentrations of the extract, while at the
highest Asafetida concentration it did not show any signiﬁ-
cant effect on 3-MM (Fig. 2). The maximum inhibition
(about 80% of control) of DOR formation was observed at
the highest concentration (100 lg/ml) of Asafetida extract.
Order of inhibition of DOR formation was observed as
100 > 50 > 25P 10 lg/ml Asafetida extract. Asafetida resin
extract at lower concentrations of 10, 25 and 50 lg/ml acti-
vates the formation of 3-MM. The activation was highest
at 25 lg/ml concentration. The highest concentration
(100 lg/ml) of Asafetida extract did not produce any remark-
able effect on the formation of 3-MM (Fig. 2).
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Figure 2 Effect of Asafetida on the formation of 3-MM from
DEX in human liver microsomes (n= 3, mean ± SD). Formation
of the metabolite is expressed as nM/mg protein/min. *P 6 0.05.
Modulation of metabolic activities of CYP2D6 and CYP3A4 by asafetida 567Clinical study also showed that Asafetida resin powder pro-
duced a potent inhibitory effect on the formation of 3-MM
and DOR. Table 1 summarizes the metabolic ratios of DEX/
DOR and DEX/3-MM, before and after administration of
Asafetida resin. The DEX/DOR was moderately increased
by Asafetida; while the increase in DEX/3-MM was
signiﬁcant. Almost 75% of DOR was excreted in urine when
compared with the control. The percent amounts of DOR
and 3-MM excreted in the urine in the presence of Asafetida
(compared to control) were about 75% and 50%, respectively.
4. Discussion
The in vitro as well as in vivo investigations were carried out to
study the effect of Asafetida resin (ethanolic extract and pow-
der) on the metabolic activities of CYP2D6 and CYP3A4
hepatic enzymes. Human liver microsomes were used for
in vitro investigation. The in vivo study was conducted on
healthy human volunteers. Dextromethorphan and its metab-
olite were measured in urine samples. In vitro microsomal
model was used as a rapid screening tool for interaction stud-
ies. However, in vitro observation does not guarantee whether
the same effect will occur in clinical practice, because the con-
tribution of some physiological factors remains unaccounted.
Therefore, clinical signiﬁcance of an in vitro study cannot be
adopted without in vivo conﬁrmation. Thus the formation of
DEX metabolites under in vitro and in vivo conditions wasTable 1 Urinary metabolic ratio (MR) of DEX with its metabolite
Subjects Urinary metabolic ratio DEX /DOR
MR, control MR, phase-II
1 0.214 0.264
2 0.015 0.026
3 0.020 0.063
4 0.054 0.072
5 0.055 0.094
6 0.076 0.057
Mean 0.072 0.096
SD 0.073 0.085
P value 0.037used to assess the metabolic activities of CYP2D6 and
CYP3A4. DEX has been used as a probe for CYP2D6 and
CYP3A4 enzymes. It is a non-narcotic antitussive agent, safe,
effective and non-invasive marker. It is metabolized by N- and
O-demethylations catalyzed by CYP2D6 and CYP3A4 to form
metabolites such as DOR and 3-MM, respectively. Asafetida
signiﬁcantly inhibited the formation of DOR in liver micro-
somes. This in vitro inhibition was observed as concentration
dependent and suggested that Asafetida may have the poten-
tial to alter the pharmacokinetics of CYP2D6. But on contrary
Asafetida potentiates the in vitro activity of CYP3A4 at lower
concentrations, but did not produce any remarkable effect at
the highest concentration.
Although activation of CYP-mediated reactions has been
reported in several previous in vitro studies (Atkins et al.,
2001; Hutzler et al., 2003; Korzekwa et al., 1998; Tracy,
2006), its in vivo relevance is still unclear. Unlike induction,
activation is not associated with an increase in the protein level
of the activated enzyme but only with its activity. One possible
mechanism of CYP3A4 activation, which has been previously
suggested by several investigators, is the presence of multiple
binding sites at the enzyme active site (Atkins et al., 2001;
Korzekwa et al., 1998; Tracy, 2006). This explanation is sup-
ported by the fact that several CYP3A4 activators are also
known to be metabolized by this enzyme. Based on that, the
activation by Asafetida observed in this in vitro study could
be due to the ability of at least one of its constituents to bind
to the CYP3A4 binding site leading to an increase in the rate of
3-MM formation possibly by inducing conformational
changes in the enzyme. Activation of CYP3A4 by Asafetida
has not been reported before and further in vitro studies that
investigate the potential effects of individual Asafetida constit-
uents would be helpful in understanding the mechanism of the
observed activation, which is out of the scope of this study.
Although in vitro metabolic activation has not been conﬁrmed
in vivo before, the opposite signiﬁcant inhibitory effect on 3-
MM observed in the clinical study is difﬁcult to explain. How-
ever, such opposite effects suggest that this interaction may be
time and concentration dependent. Dose of Asafetida and
duration of treatment may inﬂuence the outcome of the inter-
action. Another possible explanation for the signiﬁcant in vivo
inhibition that was not seen in vitro could be due to the ability
of Asafetida to affect CYP3A4 protein expression, which does
not occur in the microsomal in vitromodel and is considered to
be one of its major limitations.
Numerous clinical studies have reported the effects of some
natural products on the metabolism of conventional drugs.s in human subjects (n= 6).
Urinary metabolic ratio DEX/3-MM
MR, control MR, phase-II
7.522 12.034
2.012 3.949
4.641 16.070
5.530 7.948
1.532 3.673
1.314 1.301
3.759 7.496
2.532 5.655
0.036
568 F.I. Al-Jenoobi et al.Therefore, the clinical study was conducted to conﬁrm the
in vitro results. In vivo modulation of metabolic activity of
CYP2D6 and CYP3A4 in the presence of Asafetida was
assessed by determining the urinary metabolic ratio of DEX/
DOR and DEX/3-MM. Clinical study ﬁndings suggest that
Asafetida has a signiﬁcant inhibitory effect on human
CYP3A4 and a marginal effect on CYP2D6. These ﬁndings
were consistent with animal studies conducted on rats, wherein
oral administration of F. asafetida for one week resulted in the
reduction of mRNA and protein of CYP3A, in rat liver (Data
unpublished).
5. Conclusion
In conclusion, the signiﬁcant Asafetida inhibitory effect on
CYP3A4 metabolic activity was an important ﬁnding of this
study. Based on that, taking Asafetida with CYP3A4 drug
substrates should be cautioned, especially those known to have
narrow therapeutic index such as cyclosporine, tacrolimus,
everolimus, carbamazepine and quinidine.Declaration of interest
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